Suppr超能文献

间质性肺异常的发病率:多民族动脉粥样硬化研究(MESA)肺部研究

Incidence of interstitial lung abnormalities: the MESA Lung Study.

作者信息

McGroder Claire F, Hansen Spencer, Hinckley Stukovsky Karen, Zhang David, Nath P Hrudaya, Salvatore Mary M, Sonavane Sushilkumar K, Terry Nina, Stowell Justin T, D'Souza Belinda M, Leb Jay S, Dumeer Shifali, Aziz Muhammad U, Batra Kiran, Hoffman Eric A, Bernstein Elana J, Kim John S, Podolanczuk Anna J, Rotter Jerome I, Manichaikul Ani W, Rich Stephen S, Lederer David J, Barr R Graham, McClelland Robyn L, Garcia Christine Kim

机构信息

Department of Medicine, Columbia University Medical Center, New York, NY, USA.

Department of Biostatistics, University of Washington, Seattle, WA, USA.

出版信息

Eur Respir J. 2023 Jun 8;61(6). doi: 10.1183/13993003.01950-2022. Print 2023 Jun.

Abstract

BACKGROUND

The incidence of newly developed interstitial lung abnormalities (ILA) and fibrotic ILA has not been previously reported.

METHODS

Trained thoracic radiologists evaluated 13 944 cardiac computed tomography scans for the presence of ILA in 6197 Multi-Ethnic Study of Atherosclerosis (MESA) longitudinal cohort study participants >45 years of age from 2000 to 2012. Five percent of the scans were re-read by the same or a different observer in a blinded fashion. After exclusion of participants with ILA at baseline, incidence rates and incidence rate ratios for ILA and fibrotic ILA were calculated.

RESULTS

The intra-reader agreement of ILA was 92.0% (Gwet's AC1 0.912, intraclass correlation coefficient (ICC) 0.982) and the inter-reader agreement of ILA was 83.5% (Gwet's AC1 0.814, ICC 0.969). Incidence of ILA and fibrotic ILA was estimated to be 13.1 and 3.5 cases per 1000 person-years, respectively. In multivariable analyses, age (hazard ratio (HR) 1.06 (95% CI 1.05-1.08); p<0.001 and HR 1.08 (95% CI 1.06-1.11); p<0.001), high attenuation area at baseline (HR 1.05 (95% CI 1.03-1.07); p<0.001 and HR 1.06 (95% CI 1.02-1.10); p=0.002) and the promoter single nucleotide polymorphism (HR 1.73 (95% CI 1.17-2.56); p=0.01 and HR 4.96 (95% CI 2.68-9.15); p<0.001) were associated with incident ILA and fibrotic ILA, respectively. Ever-smoking (HR 2.31 (95% CI 1.34-3.96); p=0.002) and an idiopathic pulmonary fibrosis polygenic risk score (HR 2.09 (95% CI 1.61-2.71); p<0.001) were associated only with incident fibrotic ILA.

CONCLUSIONS

Incident ILA and fibrotic ILA were estimated by review of cardiac imaging studies. These findings may lead to wider application of a screening tool for atherosclerosis to identify pre-clinical lung disease.

摘要

背景

此前尚未报道新出现的间质性肺异常(ILA)和纤维化ILA的发病率。

方法

在多民族动脉粥样硬化研究(MESA)纵向队列研究中,从2000年至2012年,经过培训的胸放射科医生对6197名年龄大于45岁参与者的13944份心脏计算机断层扫描进行ILA检查。5%的扫描由同一名或另一名观察者以盲法重新读取。在排除基线时患有ILA的参与者后,计算ILA和纤维化ILA的发病率及发病率比。

结果

ILA的阅片者内一致性为92.0%(Gwet's AC1为0.912,组内相关系数(ICC)为0.982),ILA的阅片者间一致性为83.5%(Gwet's AC1为0.814,ICC为0.969)。ILA和纤维化ILA的发病率估计分别为每1000人年13.1例和3.5例。在多变量分析中,年龄(风险比(HR)为1.06(95%置信区间1.05 - 1.08);p < 0.001以及HR为1.08(95%置信区间1.06 - 1.11);p < 0.001)、基线时的高衰减区域(HR为1.05(95%置信区间1.03 - 1.07);p < 0.001以及HR为1.06(95%置信区间1.02 - 1.10);p = 0.002)和启动子单核苷酸多态性(HR为1.73(95%置信区间1.17 - 2.56);p = 0.01以及HR为4.96(95%置信区间2.68 - 9.15);p < 0.001)分别与新发ILA和纤维化ILA相关。曾经吸烟(HR为2.31(95%置信区间1.34 - 3.96);p = 0.002)和特发性肺纤维化多基因风险评分(HR为2.09(95%置信区间1.61 - 2.71);p < 0.001)仅与新发纤维化ILA相关。

结论

通过心脏成像研究评估了新发ILA和纤维化ILA。这些发现可能会促使更广泛地应用动脉粥样硬化筛查工具来识别临床前肺部疾病。

相似文献

1
Incidence of interstitial lung abnormalities: the MESA Lung Study.
Eur Respir J. 2023 Jun 8;61(6). doi: 10.1183/13993003.01950-2022. Print 2023 Jun.
2
Diagnostic performance of radiologists in distinguishing post-COVID-19 residual abnormalities from interstitial lung abnormalities.
Eur Radiol. 2025 Apr;35(4):2265-2274. doi: 10.1007/s00330-024-11075-x. Epub 2024 Sep 23.
3
Optimizing prone CT use for suspected interstitial lung abnormalities.
Eur Radiol. 2025 Jun;35(6):3021-3029. doi: 10.1007/s00330-024-11259-5. Epub 2024 Dec 18.
4
Genomic and Serological Rheumatoid Arthritis Biomarkers, Promoter Variant, and Interstitial Lung Abnormalities.
Ann Am Thorac Soc. 2024 Oct 15;22(1):64-71. doi: 10.1513/AnnalsATS.202403-238OC.
5
Prevalence and Long-term Outcomes of CT Interstitial Lung Abnormalities in a Health Screening Cohort.
Radiology. 2023 Feb;306(2):e221172. doi: 10.1148/radiol.221172. Epub 2022 Oct 11.
7
8
Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival.
Eur Radiol. 2022 Apr;32(4):2713-2723. doi: 10.1007/s00330-021-08378-8. Epub 2022 Jan 5.
9
A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities.
Am J Respir Crit Care Med. 2023 Oct 1;208(7):791-801. doi: 10.1164/rccm.202212-2257OC.

引用本文的文献

1
Polygenic Risk and Rare Variants in Endotypes of Idiopathic Pulmonary Fibrosis.
medRxiv. 2025 Jun 4:2025.05.22.25328177. doi: 10.1101/2025.05.22.25328177.
2
Quantitative Computed Tomography Measures of Lung Fibrosis and Outcomes in the National Lung Screening Trial.
Ann Am Thorac Soc. 2025 Sep;22(9):1314-1320. doi: 10.1513/AnnalsATS.202410-1048OC.
3
Current perspectives on interstitial lung abnormalities.
Korean J Intern Med. 2025 Mar;40(2):208-218. doi: 10.3904/kjim.2024.335. Epub 2025 Mar 1.
4
Optimizing prone CT use for suspected interstitial lung abnormalities.
Eur Radiol. 2025 Jun;35(6):3021-3029. doi: 10.1007/s00330-024-11259-5. Epub 2024 Dec 18.
5
Application of Artificial Intelligence in Thoracic Radiology: A Narrative Review.
Tuberc Respir Dis (Seoul). 2025 Apr;88(2):278-291. doi: 10.4046/trd.2024.0062. Epub 2024 Dec 17.
6
Genomic and Serological Rheumatoid Arthritis Biomarkers, Promoter Variant, and Interstitial Lung Abnormalities.
Ann Am Thorac Soc. 2024 Oct 15;22(1):64-71. doi: 10.1513/AnnalsATS.202403-238OC.
7
Progressive Early Interstitial Lung Abnormalities in Persons at Risk for Familial Pulmonary Fibrosis: A Prospective Cohort Study.
Am J Respir Crit Care Med. 2024 Dec 15;210(12):1441-1452. doi: 10.1164/rccm.202403-0524OC.
8
Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene.
Am J Respir Crit Care Med. 2024 Dec 15;210(12):1453-1460. doi: 10.1164/rccm.202402-0313OC.
9
Imaging in the diagnosis and management of fibrosing interstitial lung diseases.
Breathe (Sheff). 2024 Mar;20(1):240006. doi: 10.1183/20734735.0006-2024. Epub 2024 May 14.

本文引用的文献

1
Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives.
Eur Respir Rev. 2022 Apr 13;31(164). doi: 10.1183/16000617.0206-2021. Print 2022 Jun 30.
2
Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length.
Thorax. 2021 Dec;76(12):1242-1245. doi: 10.1136/thoraxjnl-2021-217031. Epub 2021 Apr 29.
3
Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations.
Am J Respir Crit Care Med. 2021 Mar 15;203(6):775-778. doi: 10.1164/rccm.202008-3211LE.
4
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study.
Lancet Respir Med. 2021 Mar;9(3):285-294. doi: 10.1016/S2213-2600(20)30364-7. Epub 2020 Nov 13.
5
The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality.
Am J Respir Crit Care Med. 2021 May 1;203(9):1149-1157. doi: 10.1164/rccm.202007-2993OC.
6
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.
Lancet Respir Med. 2020 Jul;8(7):726-737. doi: 10.1016/S2213-2600(20)30168-5.
7
Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis.
ERJ Open Res. 2020 Mar 2;6(1). doi: 10.1183/23120541.00115-2019. eCollection 2020 Jan.
8
Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte Telomere Length.
Am J Hum Genet. 2020 Mar 5;106(3):389-404. doi: 10.1016/j.ajhg.2020.02.006. Epub 2020 Feb 27.
9
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2020 Mar 1;201(5):564-574. doi: 10.1164/rccm.201905-1017OC.
10
Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1402-1413. doi: 10.1164/rccm.201903-0511OC.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验